Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL443700 | 0.89 | — | — | |
| Guanidine SCHEMBL28495553 | 0.78 | ALDH1A1 (0.42) | KDM4ECYP2D6CYP2C19BLMNPSR1 | |
| SCHEMBL1343067 | 0.73 | — | — | |
| SCHEMBL19506424 | 0.70 | — | — | |
| SCHEMBL5049326 | 0.70 | — | — | |
| SCHEMBL18216669 | 0.70 | — | — | |
| SCHEMBL780593 | 0.70 | — | — | |
| SCHEMBL19074182 | 0.70 | ALDH1A1 (0.38) | CA1CA2CA9 | |
| Ammonia Solution, Strong SCHEMBL16470724 | 0.70 | CA1 (0.32) | CA1CA2CA9 | |
| SCHEMBL11765134 | 0.69 | CA2 (0.31) | CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256986-A1 | Creatinol sulfate and synthesis method thereof | TIANJIN TIANCHENG PHARMACEUTICAL CO., LTD. | 2014-09-11 | — | — | US | disclosed |
| CN-101671282-B | Preparation method for creatinol sulphate | TIANJIN TIANCHENG PHARMACEUTICAL CO LTD | 2012-12-19 | — | — | CN | disclosed |
| US-20110105797-A1 | Creatinol sulfate and synthesis method thereof | TIANJIN TIANCHENG PHARMACEUTICAL CO., LTD. | 2011-05-05 | — | — | US | disclosed |
| CN-101671282-A | Preparation method for creatinol sulphate | TIANJIN TIANCHENG PHARMACEUTIC | 2010-03-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105797-A1 | Creatinol sulfate and synthesis method thereof | REN, SRM, SRMS | KDM4E 2416/4885CYP2D6 630/4885CYP2C19 867/4885 |
| US-20140256986-A1 | Creatinol sulfate and synthesis method thereof | REN, SRM, SRMS | KDM4E 2416/4885CYP2D6 630/4885CYP2C19 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.